Retinal Vein Occlusion Treatment Market 2023 to 2033: Advanced R&D Process Strategies

The global Retinal Vein Occlusion Treatment market size is predicted to be worth US$ 2.3 billion in 2023, with a compound yearly growth rate (CAGR) of 5.9% to reach US$ 4.7 billion from 2023 to 2033. Retinal vein occlusion is one of the most common retinal vascular disorders in the elderly, affecting adults over the age of 65. Age is a key risk factor for retinal vein occlusion. The incidence of retinal vein blockage is projected to rise as the geriatric population grows.

North America held a significant percentage of the global retinal vein occlusion market in 2022 due to numerous upgraded medical facilities, an increase in the occurrence of eye ailments, technological improvements, and an increase in the ageing population. The Asia Pacific retinal vein occlusion market is anticipated to grow at a 6.5% CAGR between 2023 and 2033. Rising ocular illness prevalence in Asia Pacific, particularly in China, Singapore, Indonesia, and other Southeast Asian countries, as well as rising health expenditures, are expected to drive market expansion in East and South Asia from 2023 to 2033. During the forecast years, Europe is expected to hold the second-largest market share. The growing older population, combined with increased healthcare spending, is propelling the retinal vein occlusion market in this region forward.

In 2022, the branch retinal vein occlusion sector grew the most in terms of worldwide retinal vein occlusion medicines revenue. As the prevalence of high blood pressure, cardiovascular disease, and glaucoma rises, this sector is likely to dominate the market.

Market Competition

Key players in the Retinal Vein Occlusion Treatment market are AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Kodiak Sciences Inc., Chugai Pharmaceuticals, and Novartis AG among others.

Get More Details@ https://www.futuremarketinsights.com/reports/retinal-vein-occlusion-treatment-market

Key Segments Profiled in the Retinal Vein Occlusion Treatment Industry Survey

By Drug Class:

  • Ranibizumab
  • Dexamethasone
  • Aflibercept
  • Bevacizumab

By Type:

  • Central Retinal Vein Occlusion
  • Branch Retinal Vein Occlusion

By Diagnosis:

  • Optical Coherence Tomography
  • Fundoscopic Examination
  • Fluorescein Angiography

By End User:

  • Hospitals
  • Research and Academics
  • Specialty Clinics

Comments

Post a Comment

Popular posts from this blog

Handheld Ultrasound Scanners Market Will Generate Booming Growth Opportunities to 2032

Image
According to industry predictions, the global Handheld Ultrasound Scanners Market Demand will increase at a CAGR of 9.1% from 2022 to 2032, reaching a value of US$ 472.1 million by the end of 2022. By 2032, sales are estimated to exceed a valuation of roughly US$ 1.1 billion. With an expected 83.6% market share in 2021, the wired modality now leads the sector. Because they connect to Bluetooth or Wi-Fi devices such as mobile phones or tablets, Handheld Ultrasound Scanners are gaining appeal among both medical professionals and non-radiologists. These devices improve networking systems and ease picture transfer to medical facilities. Global Handheld Ultrasound Scanners Market: Dynamics         Technological advancements in medical imaging devices, increased use of Handheld Ultrasound Scanners among non-radiologists, benefits from international trade agreements, increased importing of imaging diagnostics systems, increased use of Handheld Ultrasound Scanners in emergency medical service
Read more

Targeted Therapies for Sandhoff Disease | Assessing the Global Market Landscape

Image
The global Sandhoff Disease Therapeutics Market Size is expected to be worth US$ 10 million in 2023 and US$ 17.91 million by 2033, with a CAGR of 6% from 2023 to 2033. From 2018 to 2022, the Sandhoff Disease Treatments market increased at a 4% CAGR. According to the most recent studies, Sandhoff sickness is a rare disorder that affects 1 in 1,000,000 people. The rising demand for these medications is projected to spur the discovery of novel therapies, propelling the market forward in the coming years. Gene therapy is being investigated as a potential treatment for Sandhoff disease. The therapy restores the ability to break down GM2 ganglioside by delivering a functional copy of the missing enzyme into the patient's cells. This has the potential to reduce or stop disease progression while also improving patient quality of life. Key Takeaways from the Market Study   The Sandhoff Disease Therapeutics market increased at a 4% CAGR from 2018 to 2022. From 2023 to 2033, the global Sandh
Read more

Antidiabetics Market to reach US$ 223 billion by 2032, growing at a 9.6% CAGR from 2022 to 2032 | Future Market Insights, Inc.

Image
The global Antidiabetics Market is expected to earn US$ 223 billion while expanding at a CAGR of 9.6% during the forecast period. The rising prevalence of diabetes worldwide can be attributed to the market's expansion. The ageing baby boomer population is another factor driving the market during the forecast period. According to the International Diabetes Federation, the global diabetes incidence will increase from 366 million in 2011 to 552 million by 2030. During the forecast period, the industry is expected to benefit from a significant increase in the number of diabetic patients. Furthermore, new product development is expected to benefit the market in the near future. For example, Novo Nordisk, a Danish pharmaceutical company, announced the launch of oral semaglutide for the treatment of Type 2 diabetes in India in January 2022. Furthermore, the development of advanced pumps based on smart technologies like AI and ML is expected to open up a slew of new doors. For exampl
Read more